


LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **exenatide** (GLP-1 Receptor Agonists)
- Comparator (class): **glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	0	0	0	-
Merative CCAE	8,646	4,737	18	3.80
Merative MDCD	910	451	10	22.16
Merative MDCR	818	519	5	9.63
Optum Clinformatics	4,400	2,499	22	8.80
Optum EHR	4,484	1,791	29	16.19
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

